GucyCART

GucyCART is an investigational **GUCY2C-directed chimeric antigen receptor T-cell therapy** being developed in the research setting for **colorectal cancer**, particularly solid-tumor settings with high **guanylate cyclase C** expression. The product consists of engineered T cells designed to recognize **guanylate cyclase C**, a well-established colorectal cancer-associated surface antigen, and to kill GUCY2C-expressing tumor cells through antigen-dependent T-cell cytotoxicity. Available information indicates that GucyCART remains **preclinical**, with published mouse studies showing activity against intraperitoneal colorectal cancer models and literature discussing antigen-loss biology relevant to this platform, but no clear evidence in the provided material of commercial branding, regulatory approval, or advanced clinical-stage development.

Other names

GUCY2C-directed CAR-TGUCY-2C-directed CAR-TGUCY 2C-directed CAR-TGUCY2C CAR-TGUCY-2C CAR-TGUCY 2C CAR-T